ALX Oncology: FDA Fast Track Designation for Evorpacept and Keytruda
ADC评论
August 3, 2022
ALX Oncology’s Evorpacept Receives Fast Track Designation from FDA as First-Line Treatment for Head and Neck Squamous Cell Carcinoma ALX Oncology On August 1, ALX
